Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,301 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Pediatric Clear all
Completed No phase listed Observational Accepts healthy volunteers

Evaluating Supportive Care for Children With Cancer: A Multi-Institutional Survey Study of Pediatric Oncology Patients and Parents

NCT01273194
View directory record Official record
Conditions
Pediatric Cancer
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
10 Years to 99 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 21, 2026, 9:40 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Doxorubicin Pharmacokinetic (PK) Study

NCT00124956
View directory record Official record
Conditions
Cancer
Interventions
Doxorubicin
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Year to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 21, 2026, 9:40 AM EDT
Active, not recruiting Phase 1 Interventional

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

NCT05206357
View directory record Official record
Conditions
Non-hodgkin Lymphoma
Interventions
Epcoritamab
Drug
Lead sponsor
Genmab
Industry
Eligibility
1 Year to 25 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
8
States / cities
Palo Alto, California • Miami, Florida • Valhalla, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 21, 2026, 9:40 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

NCT03876769
View directory record Official record
Conditions
B-Cell Acute Lymphoblastic Leukemia
Interventions
CTL019
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 25 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 21, 2026, 9:40 AM EDT
Active, not recruiting Phase 1 Interventional

T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

NCT01860937
View directory record Official record
Conditions
Relapsed B-Cell Acute Lymphoblastic Leukemia
Interventions
leukapheresis or collection of PBMCs, cyclophosphamide based chemotherapy regimens, modified T cells
Procedure · Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 26 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 21, 2026, 9:40 AM EDT
Recruiting Phase 2 Interventional

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

NCT05082519
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia, Obesity
Interventions
IDEAL2 Intervention
Behavioral
Lead sponsor
Etan Orgel
Other
Eligibility
7 Years to 25 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
16
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 21, 2026, 9:40 AM EDT
Completed Phase 4 Interventional Results available

Safety and Tolerability of Zipsor® in Pediatric Subjects (Ages 12-17 Years) With Mild to Moderate Acute

NCT01982539
View directory record Official record
Conditions
Pain
Interventions
Zipsor®
Drug
Lead sponsor
Depomed
Industry
Eligibility
12 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Sheffield, Alabama • Stanford, California
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 21, 2026, 9:40 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

NCT02723994
View directory record Official record
Conditions
Leukemia
Interventions
Ruxolitinib, Asparaginase Erwinia Chrysanthemi, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Thioguanine, Vincristine Sulfate
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
1 Year to 21 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
103
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 87 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 21, 2026, 9:40 AM EDT
Completed Not applicable Interventional

Neuroplasticity-Based Cognitive Remediation for Pediatric Brain Tumor Survivors

NCT02129712
View directory record Official record
Conditions
Brain Tumor
Interventions
Cognitive training
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
7 Years to 16 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 21, 2026, 9:40 AM EDT
Not listed Not applicable Interventional

Effectiveness of EEG Neurofeedback in Pediatric Occupational Therapy to Improve Executive Functioning

NCT04221620
View directory record Official record
Conditions
Executive Functioning, Pediatric ALL
Interventions
Zengar Electroencephalogram (EEG) Neurofeedback device
Device
Lead sponsor
Northern Arizona University
Other
Eligibility
6 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Prescott, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 21, 2026, 9:40 AM EDT
Withdrawn Phase 4 Interventional

Reducing Port Access Pain and Clinic Wait Time: An Evaluation of EMLA Cream Versus nüm™ Vapocoolant Spray

NCT06023368
View directory record Official record
Conditions
Pediatric Cancer
Interventions
Num Vapocoolant Spray, EMLA Cream
Drug
Lead sponsor
Marianne Hutti
Other
Eligibility
4 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 21, 2026, 9:40 AM EDT
Withdrawn Phase 4 Interventional

Heart Safety Study of Ondansetron in Children Receiving Chemotherapy

NCT01896440
View directory record Official record
Conditions
Malignant Childhood Neoplasm
Interventions
Ondansetron
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
6 Months to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 8, 2013 · Synced Oct 21, 2026, 9:40 AM EDT
Completed Not applicable Interventional

Measuring Changes in Body Composition and Physical Function in Patients With Childhood Cancers

NCT05823740
View directory record Official record
Conditions
Cancer, Malignant Neoplasm
Interventions
Bioelectrical impedance Analysis (BIA), D3-Creatine Dilution (D3Cr), 6-Minute Walk Test (6MWT), Timed Up and Go (TUG), 30-second Sit-to-Stand (STS), Hand Grip Strength (GS), PBTL p16 expression, CT, MR and PET Imaging
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
8 Years to 21 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 21, 2026, 9:40 AM EDT
Completed Phase 2 Interventional Results available

Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation

NCT02458235
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphoid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome
Interventions
azacitidine, donor lymphocyte infusion
Drug · Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 29 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Oct 21, 2026, 9:40 AM EDT
Completed No phase listed Observational

Pediatric Vaccinations

NCT04936776
View directory record Official record
Conditions
Pediatric ALL, Vaccination, Immunization
Interventions
Text messaging
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
1 Year to 2 Years
Enrollment
1,034 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 21, 2026, 9:40 AM EDT
Recruiting Not applicable Interventional

At-Home Cardiac Rehabilitation for Adolescents at Risk for Heart Failure

NCT06826534
View directory record Official record
Conditions
Cardiovascular Complication, Chemotherapeutic Toxicity
Interventions
Cardio-oncology rehabilitation
Behavioral
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
0 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 21, 2026, 9:40 AM EDT
Completed Not applicable Interventional Results available

Insomnia Prevention in Children With Acute Lymphoblastic Leukemia

NCT05866887
View directory record Official record
Conditions
Pediatric Acute Lymphoblastic Leukemia, Leukemia, Acute Lymphoblastic Leukemia
Interventions
Sleep ALL Night
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
4 Years to 12 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 21, 2026, 9:40 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Inhaled Steroids for Pediatric Asthma at Pediatric Emergency Medicine Discharge

NCT03369847
View directory record Official record
Conditions
Asthma, Pediatric ALL
Interventions
budesonide, beclomethasone
Drug
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
Up to 18 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Oct 21, 2026, 9:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers

NCT02409121
View directory record Official record
Conditions
Leukemia, Lymphoma, Brain Tumor
Interventions
Education information system
Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
10 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 21, 2026, 9:40 AM EDT
Completed No phase listed Observational

Longitudinal Study of Biomarkers

NCT01595126
View directory record Official record
Conditions
Central Nervous System Tumor
Interventions
Not listed
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
1 Day to 21 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 21, 2026, 9:40 AM EDT
Withdrawn Phase 2 Interventional

Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population.

NCT02567149
View directory record Official record
Conditions
Warts
Interventions
Cidofovir
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 9:40 AM EDT
Completed Not applicable Interventional

Use of Transcranial Photobiomodulation to Improve Cognition and Self-Reported Outcomes in Survivors of Childhood Cancer

NCT05550948
View directory record Official record
Conditions
ALL, Hodgkin Lymphoma, Cancer, Survivorship
Interventions
Transcranial photobiomodulation (tPBM) - Mobile System
Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Results available

Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma

NCT03323034
View directory record Official record
Conditions
Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm
Interventions
Irinotecan, Pevonedistat, Temozolomide
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 21, 2026, 9:40 AM EDT
Terminated Phase 3 Interventional Results available

Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

NCT04485104
View directory record Official record
Conditions
Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Month to 23 Months
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 21, 2026, 9:40 AM EDT